CRISPR Therapeutics AG

( )
CRSP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -0.09%704.802.6%$681.87m
AMGNAmgen, Inc. 0.00%230.981.4%$641.11m
MRNAModerna, Inc. -0.52%121.520.0%$630.48m
GILDGilead Sciences, Inc. 0.00%63.931.0%$522.23m
BIIBBiogen, Inc. -1.48%272.521.8%$456.60m
VRTXVertex Pharmaceuticals, Inc. -0.17%291.911.9%$390.67m
ILMNIllumina, Inc. -2.13%197.003.2%$316.82m
SNSSSunesis Pharmaceuticals, Inc. 0.00%4.370.7%$305.48m
SAVACassava Sciences, Inc. -0.82%43.480.0%$193.39m
BNTXBioNTech SE -1.17%132.230.0%$108.45m
NVAXNovavax, Inc. -1.17%19.3875.6%$89.01m
BMRNBioMarin Pharmaceutical, Inc. 0.00%85.844.2%$84.06m
NRBONeuroBo Pharmaceuticals, Inc. 4.20%13.900.0%$80.11m
TECHBio-Techne Corp. 0.00%289.654.5%$75.91m
EXASEXACT Sciences Corp. -2.09%33.7217.6%$73.25m

Company Profile

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.